# US 2020/0368197 A1 · Pharmaceutical composition, excipient for the composition and use of the composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368197 A1
- Document ID: US20200368197A1
- Status: Published application
- Kind: A1
- Application number: 16/967,334
- Filed: 2019-02-11
- Published: 2020-11-26
- Earliest claimed: 2018-02-09
- Assignees: Prati, Donaduzzi & Cia Ltda; Universidade De SãO Paulo
- Applicants: Prati, Donaduzzi & Cia Ltda; Universidade De São Paulo
- Inventors: Luiz Donaduzzi; Carmen Maria Donaduzzi; Liberato Brum Junior; Patrícia Moura Da Rosa Zimmerman; Emanuelle Webler; Letícia Mello Rechia; José Alexandre Crippa; Jaime Eduardo Cecilio Hallak; Antonio Waldo Zuardi; Francisco Silveira Guimarães; Alline Cristina De Campos; Vitor Tumas; Elaine Aparecida Del Bel Belluz Guimarães
- Web page: https://patentgrep.com/patent/US20200368197A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition containing synthetic Cannabidiol and its use in obtaining a medication for the treatment of neurological disorders, as well as the main excipients used in the production process, in addition to its small, medium, and large-scale preparation process. The use of the composition for the treatment of neurological disorders in human or animal populations, in particular in the treatment of Parkinson's disease, in the range of 300 to 850 mg/day or at daily doses of 100 to 1750 mg for neuroprotective action.

## Claims

### Claim 1

A pharmaceutical composition comprising Cannabidiol of synthetic origin, up to 0.06% Cannabinol, up to 0.06% Delta-8-tetrahydrocannabinol, up to 0.06% Delta-9-tetrahydrocannabinol, up to 0.06% Cannabidiolic acid methyl ester, up to 0.06% Menthadienol, and up to 0.06% Methyl olivetolate.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the Cannabidiol of synthetic origin is in the range between 50 to 400 mg.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the composition is in an oral pharmaceutical form selected from the group consisting of hard gelatin capsule, tablet, coated tablet, orodispersible tablet, effervescent tablet, lozenge, syrup, suspension and/or solution, and soft gelatin capsule.

### Claim 4

An excipient for a pharmaceutical composition comprising Cannabidiol of synthetic origin, up to 0.06% Cannabinol, up to 0.06% Delta-8-tetrahydrocannabinol, up to 0.06% Delta-9-tetrahydrocannabinol, up to 0.06% Cannabidiolic acid methyl ester, up to 0.06% Menthadienol, and up to 0.06% Methyl olivetolate, the excipient comprising an oil selected from the group consisting of an oil of vegetable origin, an oil of animal origin, an oil of mineral origin, and combinations thereof.

### Claim 5 (depends on 4)

The excipient according to claim 4, wherein the oil is selected from the group consisting of grape seed oil, sesame oil, corn oil, soybean oil, olive oil, sunflower oil, canola oil, walnut oil, linseed oil, avocado oil, mint oil, peanut oil, hydrogenated castor oil, coconut oil, acai oil, andiroba oil, babassu oil, buriti oil, Brazil nut oil, oil of copaiba, passion fruit oil, pracaxi oil, pataua oil, triglycerides, primrose oil, safflower oil, almond oil, borage oil, pomegranate seed oil, sea buckthorn oil, garlic oil, krill oil, cod liver oil, palm oil, fish oil, hydrogenated castor oil, macadamia oil, rosehip oil, cotton oil, and combinations thereof.

### Claim 6 (depends on 5)

The excipient according to claim 5, wherein the oil is in the form of an oily solvent that comprises corn oil.

### Claim 7

A method for the treatment for neuroprotective action comprising the administration of a pharmaceutical composition comprising Cannabidiol of synthetic origin, up to 0.06% Cannabinol, up to 0.06% Delta-8-tetrahydrocannabinol, up to 0.06% Delta-9-tetrahydrocannabinol, up to 0.06% Cannabidiolic acid methyl ester, up to 0.06% Menthadienol, and up to 0.06% Methyl olivetolate, wherein the treatment has neuroprotective action.

### Claim 8 (depends on 7)

The method of treatment according to claim 7, wherein the administration is at the dose of 100 to 1750 mg/day.

### Claim 9

A method for the preparation of a medicament for treatment for neurological disorders comprising the preparation of a pharmaceutical composition comprising Cannabidiol of synthetic origin, up to 0.06% Cannabinol, up to 0.06% Delta-8-tetrahydrocannabinol, up to 0.06% Delta-9-tetrahydrocannabinol, up to 0.06% Cannabidiolic acid methyl ester, up to 0.06% Menthadienol, and up to 0.06% Methyl olivetolate, wherein the medicament is for treating neurological disorders.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the neurological disorders are selected from the group consisting of refractory epilepsy, epilepsy, schizophrenia, sleep disorders, post-traumatic disorder, Alzheimer's disease, anxiety, depression, bipolar disorder, neuropathic pain, chronic pain relief, autism, chronic pain relief, and Parkinson's disease.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the neurological disorder is Parkinson's disease.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the medicament is administered in a dose of Cannabidiol between 300 and 850 mg/day.

### Claim 13 (depends on 7)

The method according to claim 7, wherein the dose is a single dose or doses divided throughout the day.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the dose is a single dose or doses divided throughout the day.
